Reply to thread

From the earnings report. Falling sales and generic negotiations don’t help in dumping a brand. “Xiidra (USD 89 million, –17%, –16% cc) 97% of the sales are in the US where the variance is driven by rebates. In the US, Novartis is in ANDA litigation with a generic manufacturer.”